TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20650346

Group type: EXPERIMENTAL
Intervention: Chitosan (750 mg, 3 times per day) 30 minutes before meals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 18365858

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg (CEE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 17 beta‐estradiol 1 mg plus norethisterone acetate 0.5 mg (E(2)/NETA)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Raloxifene HCl 60 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 100
Study: 16181890

Group type: EXPERIMENTAL
Intervention: Less invasive surgical and endovascular approach for aortic arch repair
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular intervention with retrograde stent-graft placement
Number of subjects: 0
Study: 12095385

Group type: EXPERIMENTAL
Intervention: Abacavir, 300 mg twice per day, while continuing all other antiretroviral therapy (n = 54)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Continuing all antiretroviral therapy (n = 57)
Number of subjects: 111
Study: 9501885

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 336

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 336
Study: 7836531

Group type: EXPERIMENTAL
Intervention: 10% non-heat-treated serum
Number of subjects: 135

Group type: COMPARATOR
Intervention: 10% heat-treated serum
Number of subjects: 135
Study: 3169489

Group type: EXPERIMENTAL
Intervention: Pectin (15 g added to meal)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Methylcellulose (15 g added to meal, control)
Number of subjects: 9
Study: 31778465

Group type: EXPERIMENTAL
Intervention: Visual data presentation
Number of subjects: 0
Study: 30201324

Group type: EXPERIMENTAL
Intervention: 0.5 μg.kg−1 of dexmedetomidine (high Dex group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.25 μg.kg−1 of dexmedetomidine (low Dex group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (placebo group)
Number of subjects: 90
Study: 28277138

Group type: EXPERIMENTAL
Intervention: 250 mg carnitine supplements
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25787990

Group type: EXPERIMENTAL
Intervention: High-DHA enteral feeds (≈1% total fatty acids)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Standard-DHA enteral feeds (≈0.3% total fatty acids)
Number of subjects: 626
Study: 23159100

Group type: EXPERIMENTAL
Intervention: Aggressive statin therapy
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: MMP-3 levels
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: MMP-1 and MMP-2 levels
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: MMP-3 levels at follow-up
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: MMP-2 and MMP-3 levels at follow-up
Number of subjects: 248
Study: 20462570

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) plus treatment as usual (TAU)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 106
Study: 19178808

Group type: EXPERIMENTAL
Intervention: Flexible reinforced laryngeal mask airway (FRLMA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Endotracheal tube (ETT)
Number of subjects: 60
Study: 16817556

Group type: EXPERIMENTAL
Intervention: Graded dermal tuberculin test using 100%, 25%, 5%, and 1% tuberculin solution via prick test
Number of subjects: 0
Study: 12694144

Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5 micro g.ml‐1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adrenaline 1.0 micro g.ml‐1
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adrenaline 1.5 micro g.ml‐1
Number of subjects: 36

Group type: COMPARATOR
Intervention: Adrenaline 2.0 micro g.ml‐1 (standard mixture)
Number of subjects: 36
Study: 10896687

Group type: EXPERIMENTAL
Intervention: Psychotic group (Alzheimer's disease with psychotic symptoms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-psychotic group (Alzheimer's disease without psychotic symptoms)
Number of subjects: 20
Study: 9199908

Group type: EXPERIMENTAL
Intervention: Prophylactic sclerotherapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control
Number of subjects: 58
Study: 8355938

Group type: EXPERIMENTAL
Intervention: Vaginal dissection
Number of subjects: 48

Group type: COMPARATOR
Intervention: Abdominal surgery without vaginal dissection
Number of subjects: 48
Study: 3794300

Group type: EXPERIMENTAL
Intervention: 3 doses of 40 micrograms HBsAg (months 0, 1, 6)
Number of subjects: 88

Group type: COMPARATOR
Intervention: 3 doses of 10 micrograms HBsAg (healthy controls)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 6 doses of 40 micrograms HBsAg (monthly intervals)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 6 doses of 20 micrograms HBsAg (monthly)
Number of subjects: 88
Study: 29500217

Group type: EXPERIMENTAL
Intervention: Metformin (up to 2 g/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 28112286

Group type: EXPERIMENTAL
Intervention: Training EMS personnel in recognizing and initiating treatment in the prehospital setting with early administration of antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25368541

Group type: EXPERIMENTAL
Intervention: Study diet (Oxepa®; Abbott Japan) containing EPA, DHA, GLA, and antioxidants
Number of subjects: 62

Group type: COMPARATOR
Intervention: General control diet (Ensure® H; Abbott Japan)
Number of subjects: 62
Study: 22518369

Group type: EXPERIMENTAL
Intervention: Long-acting oral morphine 30 mg orally twice daily for three days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 200
Study: 20190259

Group type: EXPERIMENTAL
Intervention: Marsh PK model with k(e0)=0.26 min(‐1) (Group M)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Schnider PK model with fixed k(e0)=0.456 min(‐1) (Group S1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Schnider PK model with k(e0) adapted to a fixed time‐to‐peak effect=1.6 min (Group S2)
Number of subjects: 60
Study: 18279691

Group type: EXPERIMENTAL
Intervention: K-Y Jelly
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Replens
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ambulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Parity
Number of subjects: 6

Group type: COMPARATOR
Intervention: Body Mass Index (BMI)
Number of subjects: 6
Study: 16007008

Group type: EXPERIMENTAL
Intervention: 1% chitosan on 0.2% HCl in combination with methylene blue and IR laser beam (study group)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Chlorhexidine (control group)
Number of subjects: 68
Study: 12605026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 20 mg cariporide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 80 mg cariporide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: 120 mg cariporide
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All cariporide groups (20 mg, 80 mg, 120 mg)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 53
Study: 10382587

Group type: EXPERIMENTAL
Intervention: HOMA %S
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2‐h CIGMA %S
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: FSIVGTT‐MinMod
Number of subjects: 24

Group type: COMPARATOR
Intervention: ITT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: HOMA-CIGMA with immunoreactive insulin
Number of subjects: 24
Study: 9147928

Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intravenous cisplatinum (CDP) with 3-drug protocol (MTX, CDP, ADM)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Intravenous cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Intra-arterial cisplatinum (CDP) with 4-drug protocol (MTX, CDP, ADM, IFO)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 4-drug protocol (MTX, CDP, ADM, IFO)
Number of subjects: 149
Study: 1927982

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate mouthrinse (Peridex)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 7270654

Group type: EXPERIMENTAL
Intervention: 6-month supervised exercise program to improve physical fitness
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study: 31550774

Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome
Number of subjects: 265

Group type: COMPARATOR
Intervention: Traditional paclitaxel
Number of subjects: 265
Study: 29101258

Group type: EXPERIMENTAL
Intervention: Stroke preparedness campaign (exposed group)
Number of subjects: 1622

Group type: COMPARATOR
Intervention: Control group (nonexposed)
Number of subjects: 1622

Group type: EXPERIMENTAL
Intervention: Secondary outcome - Stroke recognition (exposed group)
Number of subjects: 1622
Study: 26724101

Group type: EXPERIMENTAL
Intervention: Cannabidiol at 2-5 mg/kg per day, up-titrated to a maximum of 25 mg/kg or 50 mg/kg per day depending on study site.
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 214
Study: 23871320

Group type: EXPERIMENTAL
Intervention: Laparoscopic common bile duct exploration plus laparoscopic cholecystectomy (LCBDE+LC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Endoscopic retrograde cholangiopancreatography plus laparoscopic cholecystectomy (ERCP+LC)
Number of subjects: 120
Study: 21668681

Group type: EXPERIMENTAL
Intervention: Oseltamivir (Tamiflu(®); Roche) 75 mg once daily prophylaxis
Number of subjects: 56

Group type: COMPARATOR
Intervention: Seasonal influenza vaccine (Fluviral(®))
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Oseltamivir prophylaxis
Number of subjects: 56
Study: 18445082

Group type: EXPERIMENTAL
Intervention: Immunotherapy with a vaccine containing 50% of the wild grasses Trisetum paniceum and Dactylis glomerata, administered with a schedule of 0.1 and 0.2 mL at day 1, followed by 0.3 and 0.5 mL at day 7, 0.5 mL after 2 weeks, and 0.5 mL monthly, totaling a mean of 6.5 injections over 2.3 months.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (Group B) with no intervention reported.
Number of subjects: 33
Study: 16807413

Group type: EXPERIMENTAL
Intervention: Homocysteine-lowering treatment (daily supplement containing folate 1000 microg, B12 500 microg, and B6 10 mg)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 12897990

Group type: EXPERIMENTAL
Intervention: Helium-oxygen mixture
Number of subjects: 23
Study: 10740555

Group type: EXPERIMENTAL
Intervention: Regional diamorphine 2.5 mg i.v.
Number of subjects: 14
Study: 9206054

Group type: EXPERIMENTAL
Intervention: Navoban (tropisetron, 5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Kytril (granisetron, 3 mg)
Number of subjects: 30
Study: 1317641

Group type: EXPERIMENTAL
Intervention: 5 x 1 mg of gemeprost every 3 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: 4 x 1 mg of gemeprost every 6 h
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 6-h gemeprost group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 50
Study: 3975430

Group type: EXPERIMENTAL
Intervention: BW245C (150 micrograms, 6-hourly for 5 days)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29431471

Group type: EXPERIMENTAL
Intervention: Higher protein hypocaloric diet (2.0 g protein/kg/d)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Standard-protein hypocaloric diet (1.0 g protein/kg/d)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both diets (higher protein and standard protein)
Number of subjects: 17
Study: 28088768

Group type: EXPERIMENTAL
Intervention: Ceftazidime/avibactam
Number of subjects: 1033
Study: 26303818

Group type: EXPERIMENTAL
Intervention: Remote ischaemic preconditioning (RIC) - three cycles of 5 min ischaemia followed by 5 min reperfusion in the upper arm immediately before surgery
Number of subjects: 69

Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 69
Study: 23169759

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR)
Number of subjects: 47
Study: 21683336

Group type: EXPERIMENTAL
Intervention: 90-μm flap
Number of subjects: 368

Group type: COMPARATOR
Intervention: 100-μm flap
Number of subjects: 368
Study: 19783371

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion (0.35mg/kg/h, not to exceed 25mg/h over a 4h period) for 10 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo infusion (normal saline) for 10 days
Number of subjects: 0
Study: 16523185

Group type: EXPERIMENTAL
Intervention: ICAPS intervention program
Number of subjects: 954

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 954
Study: 12641538

Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg) plus vitamin B6 (250 mg)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo medication
Number of subjects: 158
Study: 10858389

Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing (apneas and oxygen desaturations)
Number of subjects: 226
Study: 9174206

Group type: EXPERIMENTAL
Intervention: Amoxicillin 875 mg orally
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cefotaxime 1 g intramuscularly
Number of subjects: 12
Study: 1388195

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 16

Group type: COMPARATOR
Intervention: Untreated HIV-infected control patients
Number of subjects: 16
Study: 4023620

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of secretin for 60 min
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Combination of secretin and cholecystokinin for another 60 min
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Marker concentrations in the aspirate
Number of subjects: 103
Study: 29782468

Group type: EXPERIMENTAL
Intervention: Bacteriotherapy with Lactobacillus strains (Lactobacillus fermentum, Lactobacillus delbrueckii, Lactobacillus plantarum, Lactobacillus salivarius) for 6 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 100
Study: 26625946

Group type: EXPERIMENTAL
Intervention: 1-day paediatric simulation course
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard paediatric attachment (control group)
Number of subjects: 61
Study: 24762804

Group type: EXPERIMENTAL
Intervention: HPV primary screening
Number of subjects: 8873

Group type: COMPARATOR
Intervention: Cytology screening
Number of subjects: 8873

Group type: EXPERIMENTAL
Intervention: HPV type 16 positive at baseline
Number of subjects: 8873

Group type: EXPERIMENTAL
Intervention: HC2 cut-off of RLU/Co ≥ 2
Number of subjects: 8873

Group type: EXPERIMENTAL
Intervention: HPV vaccination with Cervarix™
Number of subjects: 8873

Group type: EXPERIMENTAL
Intervention: Primary HPV screening
Number of subjects: 8873
Study: 22283360

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM) with live nursing visits and video-based nursing visits
Number of subjects: 328

Group type: COMPARATOR
Intervention: Live nursing visits only (Control)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring (RPM)
Number of subjects: 328
Study: 20174905

Group type: EXPERIMENTAL
Intervention: Valsartan (V) 160 mg once daily
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Olmesartan (O) 20 mg once daily
Number of subjects: 74

Group type: COMPARATOR
Intervention: Amlodipine (A) 10 mg once daily
Number of subjects: 74
Study: 18344941

Group type: EXPERIMENTAL
Intervention: ATG (9 mg/kg ATG Fresenius S)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 79
Study: 17162992

Group type: EXPERIMENTAL
Intervention: Home CPAP titration (3 nights)
Number of subjects: 200

Group type: COMPARATOR
Intervention: In-laboratory CPAP titration (1 night)
Number of subjects: 200
Study: 14592587

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 11071801

Group type: EXPERIMENTAL
Intervention: Invasive strategy (on-site coronary angioplasty or emergency air-ambulance transfer for bypass grafting surgery)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conservative strategy (persistent medical treatment)
Number of subjects: 148
Study: 8828077

Group type: EXPERIMENTAL
Intervention: Experimental diet (supplemental dietary arginine, canola oil, and trace elements)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 0
Study: 1473420

Group type: COMPARATOR
Intervention: Conventional scissors excision with ligation (Group A; n = 16)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Diathermy excision without ligation (Group B; n = 33)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study: 6381006

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) using the Mill-Hill Infuser
Number of subjects: 12

Group type: COMPARATOR
Intervention: Multiple injections (MI) using the Medi-Jector
Number of subjects: 12
Study: 30807280

Group type: EXPERIMENTAL
Intervention: Beer‐NoGo
Number of subjects: 81

Group type: COMPARATOR
Intervention: Beer‐Go
Number of subjects: 81

Group type: COMPARATOR
Intervention: Oddball
Number of subjects: 81

Group type: COMPARATOR
Intervention: BAI
Number of subjects: 81
Study: 29332645

Group type: EXPERIMENTAL
Intervention: Pre-meal administration of Rifampicin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Post-meal administration of Rifampicin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Pre-meal administration of Pyrazinamide
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Post-meal administration of Pyrazinamide
Number of subjects: 52
Study: 28040121

Group type: EXPERIMENTAL
Intervention: sublingual misoprostol 400 μg
Number of subjects: 120

Group type: COMPARATOR
Intervention: intravenous oxytocin 20 units
Number of subjects: 120
Study: 24443547

Group type: EXPERIMENTAL
Intervention: NVP-based combination antiretroviral therapy (cART)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: NVP-based cART
Number of subjects: 219
Study: 21414137

Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures with splinted attachment system
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures with unsplinted attachment system
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional maxillary dentures (pre-treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures (after 1 year)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Maxillary 3-implant overdentures (after 2 years)
Number of subjects: 40
Study: 20470365

Group type: EXPERIMENTAL
Intervention: Counsellors Contact Caregivers (CCC) intervention, where general practitioners recommend family counsellors who actively contact caregivers.
Number of subjects: 110

Group type: COMPARATOR
Intervention: No specific control intervention mentioned, but 29 family members (30%) had no personal contact or only one personal contact (33 cases, 34%).
Number of subjects: 110
Study: 18158878

Group type: EXPERIMENTAL
Intervention: Triple treatment plus Lactobacillus casei strain Shirota
Number of subjects: 64

Group type: COMPARATOR
Intervention: Triple treatment alone (control)
Number of subjects: 64
Study: 16491680

Group type: EXPERIMENTAL
Intervention: Intervention group (posters and lectures promoting participation in physical activity for 12 weeks)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 366
Study: 11791032

Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Losartan + Quinapril
Number of subjects: 105

Group type: COMPARATOR
Intervention: Amlodipine + Quinapril
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Quinapril (10 mg) followed by Losartan (50 mg) or Amlodipine (5 mg)
Number of subjects: 105
Study: 10416748

Group type: EXPERIMENTAL
Intervention: 5% carbogen for 7 minutes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 100% oxygen for 7 minutes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Increased IOP to 50 mm Hg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 0.5% betaxolol (betoptic)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 0.5% timolol (timoptic)
Number of subjects: 5
Study: 7575714

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 22
Study: 2205799

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass surgery
Number of subjects: 838
Study: 6118859

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 100
Study: 30993696

Group type: COMPARATOR
Intervention: NaOCl
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NaOCl/HEDP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 28846122

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy (OMTh)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham therapy (control)
Number of subjects: 50
Study: 25616647

Group type: EXPERIMENTAL
Intervention: Nimotuzumab 400 mg weekly added to standard radiochemotherapy followed by 400 mg biweekly after twelve weeks
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard radiochemotherapy
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Nimotuzumab in patients with residual tumour
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard radiochemotherapy in patients with residual tumour
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Nimotuzumab in patients without residual tumour
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard radiochemotherapy in patients without residual tumour
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Nimotuzumab in MGMT non-methylated patients with residual tumour
Number of subjects: 149

Group type: COMPARATOR
Intervention: Standard radiochemotherapy in MGMT non-methylated patients with residual tumour
Number of subjects: 149
Study: 23823078

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (ivB)
Number of subjects: 0